All Hong Kong stocks quotes are at least 15 minutes delayed.
01801
INNOVENT BIO
HKD
89.3000.300
(0.34%)
1D
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
News
![an image of [object Object]](/_next/image?url=https%3A%2F%2Fd5bp8bijhhba2.cloudfront.net%2Fimage%2Fdefault_image%2Fprnewswire.png&w=384&q=75)
9.0
01-09PRnewswirePinnedInnovent's OLN324 Clinical Trial Shows Significant Superiority Over Market Leader
- Clinical Trial Success: Innovent's partner Ollin reported that OLN324 demonstrated up to 60-fold higher anti-Ang2 potency in the JADE trial involving over 160 patients, establishing it as a potential first-line treatment for diabetic macular edema, which could reshape the market landscape.
- Retinal Drying Improvement: Patients treated with OLN324 4mg experienced approximately 75% greater retinal drying improvement at Week 1 compared to faricimab, indicating a significant therapeutic advantage that may lead to broader applications in ophthalmology.
- Significant Market Potential: The success of OLN324 positions it to capture a substantial share of the ~$15 billion global retinal therapeutics market, further solidifying Innovent's leadership in the biopharmaceutical sector.
- Future Development Plans: Ollin plans to present the JADE study results at the upcoming J.P. Morgan Healthcare Conference and aims to expedite OLN324 into global Phase 3 trials, reflecting strong confidence in the drug's future market prospects.
![an image of [object Object]](/_next/image?url=https%3A%2F%2Fd5bp8bijhhba2.cloudfront.net%2Fimage%2Fcover_image%2F4c9e8af06ece7f2ddf3caec2331ba311102420e0f30fa882a8170d443e50bdfb.png&w=384&q=75)
4.5
01-07aastocks<Midday Update> HSI Falls 272 Points; HSTI Declines by 96 Points; BABA Drops More Than 4%; CHINAHONGQIAO, CHINA LIFE, NANSHAN AL INTL, ND PAPER, CMOC Reach New Peaks
Market Performance: The Hang Seng Index (HSI) fell by 272 points (1.0%) to 26,438, while the Hang Seng Tech Index (HSTI) and the Hang Seng China Enterprises Index (HSCEI) also experienced declines of 1.7% and 1.1%, respectively.
Active Heavyweights: Major stocks like Alibaba, Meituan, Tencent, and Xiaomi saw significant drops, with Alibaba down 4% and Tencent down nearly 2%, amidst high short selling ratios.
Gainers in the Market: Wuxi Apptec and Chinahongqiao were among the notable gainers, with Wuxi Apptec rising 3.97% and Chinahongqiao hitting a new high with a 3.8% increase.
Notable Movers: Nanshan Al Intl and TYK Medicines-B experienced substantial gains, with Nanshan Al Intl up 14.5% and TYK Medicines-B up 11.1%, both reaching new highs.
![an image of [object Object]](/_next/image?url=https%3A%2F%2Fd5bp8bijhhba2.cloudfront.net%2Fimage%2Fcover_image%2Fae53fbbb81e3c3526548ee5b5d64f6b5466e58bff5747905af24ff745fc788bd.png&w=384&q=75)
4.5
01-05aastocks<Midday Update> HSI Ends Midday at 26,316, Decreasing by 21 Points; HSTI Ends Midday at 5,726, Dropping 10 Points; PING AN Rises Over 3%; PING AN, CHINA LIFE, NCI, CHALCO, CIMC ENRIC Reach New Peaks
Market Performance: The Hang Seng Index (HSI) fell by 21 points (0.1%) to 26,316, while the Hang Seng Tech Index (HSTI) and the Hang Seng China Enterprises Index (HSCEI) also experienced slight declines.
Active Heavyweights: Notable stock movements included PING AN rising 3.2% to a new high, while XIAOMI dropped 2.5%. Other significant gainers included BABA and KUAISHOU-W, with increases of 2.3% and 9.7%, respectively.
Short Selling Trends: PING AN had a short selling ratio of 27.163%, while XIAOMI's was notably higher at 30.498%. Several stocks, including XPENG and PETROCHINA, faced significant short selling pressures.
Top Gainers and Losers: Among the top gainers were BRAINAURORA-B and MICROPORT NEU, with increases of 19.9% and 17.2%. Conversely, XPENG and CNOOC were among the biggest losers, declining by 4.5% and 3.5%, respectively.
![an image of [object Object]](/_next/image?url=https%3A%2F%2Fd5bp8bijhhba2.cloudfront.net%2Fimage%2Fcover_image%2F080cd2d84418417c958b73233de628f603c83269c91123a537ec8ded74400674.jpg&w=384&q=75)
4.0
01-05aastocksDaiwa Selects INNOVENT BIO (01801.HK) and HENGRUI PHARMA (600276.SH) as Top Picks, Raises Target Price to HKD112
Market Overview: In 2025, the Chinese biopharmaceutical sector experienced significant growth, prompting Daiwa to suggest a selective investment strategy for 2026, focusing on quality stocks.
Top Stock Picks: Daiwa's recommended stocks include INNOVENT BIO, with a target price increase from HKD95 to HKD112, and HENGRUI PHARMA, maintaining a target price of RMB80.
Stock Downgrades: AKESO has been downgraded from Buy to Hold, despite an increase in its target price from HKD100 to HKD116, while CSPC PHARMA retains a Sell rating with a target price of HKD6.6.
Short Selling Data: The report includes short selling figures for the mentioned stocks, indicating varying levels of market activity and investor sentiment.
![an image of [object Object]](/_next/image?url=https%3A%2F%2Fd5bp8bijhhba2.cloudfront.net%2Fimage%2Fcover_image%2F82def9954768a9b19585155de7c628c708e73cde9d1f8fb55bb513a4c20f7888.jpg&w=384&q=75)
6.5
2025-12-31aastocks<Outlook>CCBI and SPDBI's Preferred Hong Kong Stocks (Table)
CCBI's Top Ten Focus Stocks for 2026: CCBI has identified ten key stocks for 2026, including BABA-W, TENCENT, and INNOVENT BIO, with varying short selling ratios indicating market sentiment.
SPDBI's 2026 Outlook Report: SPDBI also released a report highlighting a stock portfolio to monitor, featuring TENCENT and BABA-W, alongside other stocks like HENGRUI PHARMA and POP MART, with significant short selling activity.
Market Trends: Both reports reflect a cautious market environment, with notable short selling ratios for several stocks, suggesting investor skepticism about their performance.
Stock Performance Overview: The reports detail stock price changes and short selling data, indicating a mix of declines and slight gains among the highlighted companies, with some stocks experiencing high short selling ratios.
Money Flow
Over the past 66 trading days, overall net money flow is 298.96M, with retail investors contributing 37.22M and major investors adding 172.26M.
Net Buy $ Volume
Net Sell $ Volume
JPMorgan
Overweight
downgrade
$166 -> $149
2025-12-19
Reason
The analyst rating from JPMorgan is based on the belief that the fundamentals of the Chinese healthcare sector remain unchanged despite recent market weakness. The report suggests that the pullback in the sector, attributed to national medical insurance drug list price negotiations and profit-taking, presents a favorable entry point for investments looking towards 2026. JPMorgan specifically favors biotechnology and CXO stocks, highlighting top picks and maintaining Overweight ratings for several companies, indicating a positive outlook for their performance.
JPMorgan
Overweight
Price Target
$166 -> $149
2025-12-19
downgrade
The analyst rating from JPMorgan is based on the belief that the fundamentals of the Chinese healthcare sector remain unchanged despite recent market weakness. The report suggests that the pullback in the sector, attributed to national medical insurance drug list price negotiations and profit-taking, presents a favorable entry point for investments looking towards 2026. JPMorgan specifically favors biotechnology and CXO stocks, highlighting top picks and maintaining Overweight ratings for several companies, indicating a positive outlook for their performance.
JPMorgan
JPMorgan
maintain
$110
2025-12-09
Reason
The analyst rating from JPMorgan for INNOVENT BIO is "Overweight." The reasoning behind this rating includes:
1. Market Potential: The weight loss drug market in China is considered vast, providing significant opportunities for multiple blockbuster drugs, which supports optimism about INNOVENT BIO's prospects.
2. Product Pipeline: JPMorgan is optimistic about INNOVENT BIO's product pipeline, which covers various fields such as oncology, autoimmune diseases, metabolic diseases, and ophthalmology.
3. Flexible Pricing Strategy: Despite concerns regarding competition from Eli Lilly's tirzepatide, JPMorgan believes that INNOVENT BIO's mazdutide can adopt a flexible pricing strategy in response to market changes.
4. Future Growth Forecast: The broker forecasts that by 2027, INNOVENT BIO will have more than ten products on the market, with projected sales reaching RMB17 billion.
Overall, these factors contribute to a positive outlook for the company, justifying the "Overweight" rating.
JPMorgan
Price Target
$110
2025-12-09
maintain
The analyst rating from JPMorgan for INNOVENT BIO is "Overweight." The reasoning behind this rating includes:
1. Market Potential: The weight loss drug market in China is considered vast, providing significant opportunities for multiple blockbuster drugs, which supports optimism about INNOVENT BIO's prospects.
2. Product Pipeline: JPMorgan is optimistic about INNOVENT BIO's product pipeline, which covers various fields such as oncology, autoimmune diseases, metabolic diseases, and ophthalmology.
3. Flexible Pricing Strategy: Despite concerns regarding competition from Eli Lilly's tirzepatide, JPMorgan believes that INNOVENT BIO's mazdutide can adopt a flexible pricing strategy in response to market changes.
4. Future Growth Forecast: The broker forecasts that by 2027, INNOVENT BIO will have more than ten products on the market, with projected sales reaching RMB17 billion.
Overall, these factors contribute to a positive outlook for the company, justifying the "Overweight" rating.
CCBI
CCBI
Outperform
maintain
$125 -> $128
2025-11-07
Reason
The analyst rating for INNOVENT BIO was influenced by several positive factors highlighted in the article. The company's total product revenue for 3Q25 grew by over 40% year-over-year, exceeding expectations and surpassing the broker's full-year growth forecast of 37%. Additionally, the revenue increased by 22% quarter-over-quarter, which was a faster pace compared to the previous year.
CCBI, the research firm, views INNOVENT BIO as a leader in China's biologics market for treating challenging chronic and fatal diseases, prompting them to raise their revenue forecasts for the company for 2025-27. They also increased the adjusted earnings forecasts for the same period. As a result of these strong performance indicators and positive outlook, CCBI raised the target price for INNOVENT BIO from HKD 125 to HKD 128 while maintaining an "Outperform" rating.
CCBI
Outperform
Price Target
$125 -> $128
2025-11-07
maintain
The analyst rating for INNOVENT BIO was influenced by several positive factors highlighted in the article. The company's total product revenue for 3Q25 grew by over 40% year-over-year, exceeding expectations and surpassing the broker's full-year growth forecast of 37%. Additionally, the revenue increased by 22% quarter-over-quarter, which was a faster pace compared to the previous year.
CCBI, the research firm, views INNOVENT BIO as a leader in China's biologics market for treating challenging chronic and fatal diseases, prompting them to raise their revenue forecasts for the company for 2025-27. They also increased the adjusted earnings forecasts for the same period. As a result of these strong performance indicators and positive outlook, CCBI raised the target price for INNOVENT BIO from HKD 125 to HKD 128 while maintaining an "Outperform" rating.
CMBI
CMBI
Buy
maintain
2025-10-24
Reason
The analyst rating for INNOVENT BIO was maintained at "Buy" due to the announcement of a global strategic partnership with Takeda Pharmaceutical, which includes significant upfront payments and potential milestone payments that enhance the company's financial outlook. CMBI expressed optimism about the global development of key oncology assets IBI363 and IBI343, leading to an increase in the target price from $109.48 to $110.62 based on the discounted cash flow (DCF) method.
CMBI
Buy
Price Target
2025-10-24
maintain
The analyst rating for INNOVENT BIO was maintained at "Buy" due to the announcement of a global strategic partnership with Takeda Pharmaceutical, which includes significant upfront payments and potential milestone payments that enhance the company's financial outlook. CMBI expressed optimism about the global development of key oncology assets IBI363 and IBI343, leading to an increase in the target price from $109.48 to $110.62 based on the discounted cash flow (DCF) method.
JPMorgan
JPMorgan
maintain
$114 -> $110
2025-10-23
Reason
The analyst rating for INNOVENT BIO was reaffirmed as "Overweight" by JPMorgan due to the company's recent global collaboration agreement with Takeda Pharmaceutical, which includes a significant upfront payment and potential milestone payments. This agreement is seen as a strategic move that strengthens INNOVENT BIO's market position in the US and enhances its capabilities for independent global clinical development and commercialization. Despite trimming the target price from $114 to $110, the overall outlook remains positive, leading to the continued endorsement as a top pick in China's biopharma sector.
JPMorgan
Price Target
$114 -> $110
2025-10-23
maintain
The analyst rating for INNOVENT BIO was reaffirmed as "Overweight" by JPMorgan due to the company's recent global collaboration agreement with Takeda Pharmaceutical, which includes a significant upfront payment and potential milestone payments. This agreement is seen as a strategic move that strengthens INNOVENT BIO's market position in the US and enhances its capabilities for independent global clinical development and commercialization. Despite trimming the target price from $114 to $110, the overall outlook remains positive, leading to the continued endorsement as a top pick in China's biopharma sector.
CLSA
CLSA
upgrade
2025-10-23
Reason
The analyst rating for INNOVENT BIO was influenced by the positive outlook stemming from its global strategic collaboration with Takeda Pharmaceutical. CLSA viewed this partnership favorably for INNOVENT BIO's global expansion and product development, particularly in advancing the core project IBI363. As a result of this collaboration, CLSA raised its sales and net profit forecasts significantly for FY26 and made a slight increase for FY27. Consequently, the target price for INNOVENT BIO was increased, and the Outperform rating was maintained.
CLSA
Price Target
2025-10-23
upgrade
The analyst rating for INNOVENT BIO was influenced by the positive outlook stemming from its global strategic collaboration with Takeda Pharmaceutical. CLSA viewed this partnership favorably for INNOVENT BIO's global expansion and product development, particularly in advancing the core project IBI363. As a result of this collaboration, CLSA raised its sales and net profit forecasts significantly for FY26 and made a slight increase for FY27. Consequently, the target price for INNOVENT BIO was increased, and the Outperform rating was maintained.
BofA Securities
BofA Securities
Buy
maintain
$113
2025-10-23
Reason
The analyst rating from BofA Securities for INNOVENT BIO was raised to "Buy" due to the company's strategic collaboration with Takeda Pharmaceutical, which includes significant upfront payments and potential milestone payments. This collaboration is seen as a demonstration of INNOVENT BIO's research and development capabilities and asset value, marking a crucial step towards becoming a multinational pharmaceutical company. As a result, BofA Securities increased its revenue and EPS forecasts for 2026 and 2027, leading to an elevated target price for the stock.
BofA Securities
Buy
Price Target
$113
2025-10-23
maintain
The analyst rating from BofA Securities for INNOVENT BIO was raised to "Buy" due to the company's strategic collaboration with Takeda Pharmaceutical, which includes significant upfront payments and potential milestone payments. This collaboration is seen as a demonstration of INNOVENT BIO's research and development capabilities and asset value, marking a crucial step towards becoming a multinational pharmaceutical company. As a result, BofA Securities increased its revenue and EPS forecasts for 2026 and 2027, leading to an elevated target price for the stock.
Nomura
Nomura
Buy
maintain
2025-08-28
Reason
Nomura
Buy
Price Target
2025-08-28
maintain
Valuation Metrics
Forward PE
N/A
5Y Average PE
77.42
Current PE
50.91
Overvalued PE
527.78
Undervalued PE
-372.93
Forward EV/EBITDA
N/A
5Y Average EV/EBITDA
-40.97
Current EV/EBITDA
63.34
Overvalued EV/EBITDA
125.71
Undervalued EV/EBITDA
-207.66
Forward PS
5Y Average PS
9.98
Current PS
8.00
Overvalued PS
15.37
Undervalued PS
4.59
Financials
Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
Net Margin - %
Trading Trends
Daily
Monthly
No data
Short Selling
People Also Watch